DrugBiological
Epratuzumab clinical trials
- studies test it
- 27
- open now
- 0
- in phase 3
- 8
- first study started
- 2001
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
26 studies that test it; most in 2010 (5)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 16
- Phase 3
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 11
UCB Pharma (12) · Nantes University Hospital (2) · Alliance for Clinical Trials in Oncology (2) · Gilead Sciences (2) · Jonsson Comprehensive Cancer Center (2) · Charite University, Berlin, Germany (1) · Children's Oncology Group (1) · SWOG Cancer Research Network (1)
Often tested with
Tested in the same studies.
Rituximab (2) · Clofarabine (1) · Cytarabine (1) · Yttrium Y-90 epratuzumab tetraxetan (1)
Studies
Open first, then newest update. How each study uses epratuzumab is read from its arms, and is right about nine times in ten.
Testing it · 27
- Multi-centric StudyCompletedPhase 2Nantes University HospitalNCT01219816Written as Epratuzumab
- International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010CompletedPhase 3Charite University, Berlin, GermanyNCT01802814Written as SR-A + Epratuzumab
- Study of Epratuzumab (hLL2) in Patients With Waldenstrom's MacroglobulinemiaTerminatedPhase 2Gilead SciencesNCT00113802Written as Epratuzumab (hLL2- anti-CD22 humanized antibody)
- Study of 90Y-hLL2 to Treat Non-Hodgkin's LymphomaTerminatedPhase 1Gilead SciencesNCT00054834Written as hLL2 (epratuzumab)
- Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)CompletedPhase 3UCB PharmaNCT01261793Written as Epratuzumab
- Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00301821Written as epratuzumab
- Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus ErythematosusCompletedPhase 3UCB PharmaNCT01408576Written as Epratuzumab
- Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus ErythematosusCompletedPhase 3UCB PharmaNCT01262365Written as Epratuzumab
- Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)CompletedPhase 1/2Children's Oncology GroupNCT00098839Written as epratuzumab
- S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedPhase 2SWOG Cancer Research NetworkNCT00945815Written as epratuzumab
- Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin LymphomaCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00553501Written as epratuzumab
- Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) SubjectsCompletedPhase 2UCB PharmaNCT01534403Written as Epratuzumab
- Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the BloodCompletedPhase 1UCB Biopharma S.P.R.L.NCT02306629Written as Epratuzumab sc
- Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+Status unknownPhase 1/2Nantes University HospitalNCT01354457Written as Epratuzumab and 90Y-Epratuzumab
- Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)TerminatedPhase 2M.D. Anderson Cancer CenterNCT00941928Written as Epratuzumab
- Study of Epratuzumab in Systemic Lupus ErythematosusWithdrawnPhase 3UCB PharmaNCT00382837Written as Epratuzumab
- Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)CompletedPhase 1/2UCB PharmaNCT01449071Written as Epratuzumab 400 mg
- Epratuzumab in Treating Patients With Non-Hodgkin's LymphomaStatus unknownPhase 2Jonsson Comprehensive Cancer CenterNCT00042913Written as epratuzumab
- Epratuzumab in Treating Patients With Non-Hodgkin's LymphomaStatus unknownPhase 3Jonsson Comprehensive Cancer CenterNCT00022685Written as epratuzumab
- Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active DiseaseCompletedPhase 2UCB PharmaNCT00660881Written as Epratuzumab
Codes
What other systems call epratuzumab · ClinicalTrials.gg INT004428
- MeSH (NLM) C448700epratuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 3062P60MH9EPRATUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3730737epratuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1887EpratuzumabOne source FDA
- DrugBank DB04958One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C448700 | epratuzumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 3062P60MH9 | EPRATUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3730737 | epratuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1887 | Epratuzumab | One source FDA |
| DrugBank | DB04958 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.